The use of High Flow Nasal Cannula during care manoeuvres in patients (hospitalized adults) with SARS-CoV-2 infection: retrospective cohort study.
Article Sidebar
Main Article Content
Abstract
INTRODUCTION
14% of patients with SARS-cov-2 infection progress to hypoxia respiratory failure requiring oxygen therapy. The objective of the study is to assess the effectiveness and safety of high-flow nasal oxygen (HFNC) during assistive maneuvers (personal hygiene, self-care and nutrition) in patients with SARS-cov-2 infection.
MATERIALS AND METHODS
With a retrospective cohort study design with a statistical analysis of inferential type, in three subintensive departments of the Local Health Authority of Asti from 8 November 2020 to 20 January 2021, the documentation of patients from 41 to 100 years old with SARS-cov-2 infection who used HFNCs during assistive maneuvers alternating with the CPAP helmet/mask was examined. For the research of the sample was used the program Dshop®, in which the ages, the percentages of FiO2 and the cmh2o of PEEP administered to the patients were collected and ventilation parameters were detected.
RESULTS
Analysis of 536 medical records 114 were included in the study. There was a significant reduction in po2 and po2/FiO2 ratio and a decrease in spo2 in the oldest age group in the sample [91-100] when using HFNC. With regard to FiO2, a significant reduction in spo2 and P/F was shown with the administration of FiO2 by 90-100%. Finally, with the HFNC the values of HCO3 and lactates are contained in the optimal values of the EGA unlike the helmet/ mask CPAP with PEEP of 15 cmh2o.
DISCUSSION AND CONCLUSIONS
The HFNC is associated with increased comfort in fact the patient can hydrate, feed, perform hygiene and self-care independently. The CPAP ventilatory mode, on the other hand, requires a strong human-device collaboration, the patients often turn out to be anxious, claustrophobic and not adherent.
Downloads
Article Details
The authors agree to transfer the right of their publication to the Journal, simultaneously licensed under a Creative Commons License - Attribution that allows others to share the work indicating intellectual authorship and the first publication in this magazine.
References
[2] Procopio, G Cancelliere, G e Trecarichi, EM. (2020). “Oxygen therapy via high flow nasal cannula in severe res-piratory failure caused by Sars-Cov-2 infection: a real-life observational study”. Ther Adv Respir Dis, 14-7.
[3] World Health Organization. “WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]”. WHO Coronavirus (COVID-19); 11 agosto 2021 [consultato l'11 agosto 2021]. Disponibile all'indirizzo: https://covid19.who.int/.
[4] Geng, S Mei, Q e Zhu, C. (2020). “High flow nasal cannula is a good treatment option for COVID-19”. Heart Lung, 49(5), 444-5.
[5] Asta M. “Covid. Casco VS ossigeno nasale ad alti flussi. Studio italiano sull'efficacia”. Infermieristicamente Nur-sid [Internet]. 29 marzo 2021 [consultato il 24 luglio 2021]. Disponibile all'indirizzo: https://www.infermieristicamente.it/articolo/13566/covid-casco-vs-ossigeno-nasale-ad-alti-flussi-studio-italiano-sullefficacia
[6] Papachatzakis, Nikolaidis e Kontogiannis, S. (2020). “High-Flow Oxygen through Nasal Cannula vs. Non-Invasive Ventilation in Hypercapnic Respiratory Failure: A Randomized Clinical Trial”. Int J Environ Res Public Health, 17(16) 5994.
[7] Parke, RL e McGuinness, SP. (2013). “Pressures Delivered By Nasal High Flow Oxygen During All Phases of the Respiratory Cycle”. Respir Care, 58(10), 1621-24.
[8] Cosimo, F Facciolongo, N e Tonelli, R. (2020). “Feasibility and clinical impact of out-of-ICU noninvasive respira-tory support in patients with”. Eur Respir J, 56(5), 2002130.
[9] Suhail, R Nava, S e Carpati, C. (2020). “High-Flow, Noninvasive Ventilation and Awake (Nonintubation) Proning in Patients With Coronavirus Disease 2019 With Respiratory Failure”. Chest, 158(5), 1992-2002.